Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Colloids Surf B Biointerfaces ; 189: 110834, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-32066088

RESUMEN

An interdigitated immunosensor for Cystatin C detection based on polypyrrole/carbon nanotube electrochemical capacitor is described. Cystatin C (CysC) is powerful biomarker for early acute renal failure and one predictive for cardiovascular risk, sepsis, cancer and death. Recently, electrochemical immunosensors based on interdigitated electrodes (IDE) have been successfully focused on development of point-of-care testing, due to their miniaturization facilities and higher sensitivity as compared with the screen-printed electrochemical sensing. Herein, a polypyrrole/carbon nanotube nanoyhibrid film was grafted on two gold fingers by electropolymerization obtaining a supercapacitor. Anti-CysC antibodies were immobilized on the IDE by covalent entrapment via ethylenediamine bifunctional agent, followed by glycine blocking in acid and alkaline medium. Under low frequency, capacitive effect of antigen-antibody interaction were observed by double layer capacitance, and analytical responses of this IDE immunosensor to CysC serum were obtained by changes on phase angle a linear range up to 300 ng/mL. The cutoff was calculated for serum samples showing a total reducing of non-specific binding at approximately 28 ng/mL CysC. This immunosensor based on interdigitated electrode (IDE) is a potential tools as portable device,with possibility to use as a practical and rapid test for CysC diagnostic in samples of serum.


Asunto(s)
Técnicas Biosensibles , Cistatina C/sangre , Técnicas Electroquímicas , Inmunoensayo , Nanotubos de Carbono/química , Polímeros/química , Pirroles/química , Biomarcadores/sangre , Electrodos , Humanos , Tamaño de la Partícula , Propiedades de Superficie
2.
Eur J Gastroenterol Hepatol ; 26(1): 26-32, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24168842

RESUMEN

OBJECTIVE: We aimed to identify the clinical and genetic [IL23 receptor (IL23R) single nucleotide polymorphisms (SNPs)] predictors of response to therapy in patients with ulcerative colitis. PATIENTS AND METHODS: A total of 174 patients with ulcerative colitis, 99 women and 75 men, were included. The mean age of the patients was 47±15 years and the mean disease duration was 11±9 years. The number of patients classified as responders (R) or nonresponders (NR) to several therapies was as follows: 110 R and 53 NR to mesalazine (5-ASA), 28 R and 20 NR to azathioprine (AZT), 18 R and 7 NR to infliximab. Clinical and demographic variables were recorded. A total of four SNPs were studied: IL23R G1142A, C2370A, G43045A, and G9T. Genotyping was performed by real-time PCR using Taqman probes. RESULTS: Older patients were more prone to respond to 5-ASA (P=0.004), whereas those with pancolitis were less likely to respond to such therapies (P=0.002). Patients with extraintestinal manifestations (EIMs) were less likely to respond to 5-ASA (P=0.001), AZT (P=0.03), and corticosteroids (P=0.06). Carriers of the mutant allele for IL23R SNPs had a significantly higher probability of developing EIMs (P<0.05), a higher probability of being refractory to 5-ASA (P<0.03), but a higher likelihood of responding to AZT (P=0.05). A significant synergism was observed between IL23R C2370A and EIMs with respect to nonresponse to 5-ASA (P=0.03). CONCLUSION: Besides extent of disease and age at disease onset, the presence of EIMs may be a marker of refractoriness to 5-ASA, corticosteroids, and AZT. IL23R SNPs are associated both with EIMs and with nonresponse to 5-ASA and corticosteroids.


Asunto(s)
Antiinflamatorios/uso terapéutico , Colitis Ulcerosa/genética , Colitis Ulcerosa/terapia , Fármacos Gastrointestinales/uso terapéutico , Polimorfismo de Nucleótido Simple , Receptores de Interleucina/genética , Corticoesteroides/uso terapéutico , Adulto , Factores de Edad , Anticuerpos Monoclonales/uso terapéutico , Azatioprina/uso terapéutico , Colitis Ulcerosa/inmunología , Femenino , Predisposición Genética a la Enfermedad , Humanos , Infliximab , Masculino , Mesalamina/uso terapéutico , Persona de Mediana Edad , Fenotipo , Portugal , Estudios Retrospectivos , Factores de Riesgo , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
3.
PLoS One ; 7(9): e44312, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22957062

RESUMEN

The development of multidrug resistance (MDR) limits the efficacy of continuous chemotherapeutic treatment in chronic myelogenous leukemia (CML). Low molecular weight protein tyrosine phosphatase (LMW-PTP) is up-regulated in several cancers and has been associated to poor prognosis. This prompted us to investigate the involvement of LMW-PTP in MDR. In this study, we investigated the role of LMW-PTP in a chemoresistant CML cell line, Lucena-1. Our results showed that LMW-PTP is highly expressed and 7-fold more active in Lucena-1 cells compared to K562 cells, the non-resistant cell line. Knocking down LMW-PTP in Lucena-1 cells reverted chemoresistance to vincristine and imatinib mesylate, followed by a decrease of Src and Bcr-Abl phosphorylation at the activating sites, inactivating both kinases. On the other hand, overexpression of LMW-PTP in K562 cells led to chemoresistance to vincristine. Our findings describe, for the first time, that LMW-PTP cooperates with MDR phenotype, at least in part, through maintaining Src and Bcr-Abl kinases in more active statuses. These findings suggest that inhibition of LMW-PTP may be a useful strategy for the development of therapies for multidrug resistant CML.


Asunto(s)
Resistencia a Antineoplásicos , Proteínas Tirosina Fosfatasas/antagonistas & inhibidores , Familia-src Quinasas/metabolismo , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Antineoplásicos/farmacología , Caspasa 3/metabolismo , Línea Celular Tumoral , Supervivencia Celular , Proteínas de Fusión bcr-abl/genética , Proteínas de Fusión bcr-abl/metabolismo , Proteínas de Fusión bcr-abl/fisiología , Regulación Leucémica de la Expresión Génica , Humanos , Células K562 , Peso Molecular , Fosforilación , Proteínas Tirosina Fosfatasas/genética
4.
Bioorg Med Chem ; 16(21): 9588-95, 2008 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-18835720

RESUMEN

The anti-inflammatory properties of a heparin-like compound from the shrimp Litopenaeus vannamei are related. Besides reducing significantly (p<0.001) the influx of inflammatory cells to injury site in a model of acute inflammation, shrimp heparin-like compound was able to reduce the matrix metalloproteinase (MMPs) activity in the peritoneal lavage of inflamed animals. Moreover, this compound also reduced almost 90% the activity of MMP-9 secreted by human activated leukocytes. Negligible anti-coagulant activities in aPPT assay and a poor bleeding potential make this compound a better alternative than mammalian heparin as a possible anti-inflammatory drug.


Asunto(s)
Antiinflamatorios/farmacología , Anticoagulantes/farmacología , Glicosaminoglicanos/farmacología , Heparina/farmacología , Inflamación/tratamiento farmacológico , Penaeidae/fisiología , Animales , Antiinflamatorios/química , Anticoagulantes/química , Endotelio Vascular/citología , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/metabolismo , Glicosaminoglicanos/química , Glicosaminoglicanos/aislamiento & purificación , Hemorragia/tratamiento farmacológico , Heparina/química , Heparina/aislamiento & purificación , Heparitina Sulfato/metabolismo , Leucocitos/efectos de los fármacos , Leucocitos/enzimología , Metaloproteinasa 9 de la Matriz/metabolismo , Neutrófilos/efectos de los fármacos , Cavidad Peritoneal/fisiología , Conejos , Ratas , Porcinos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA